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In a recent issue of Cell, Silva and colleagues reported the identification of CYFIP1, a member of the actin-
assembly-promoting Scar/WAVE complex, as an invasion suppressor in epithelial cancers. This study
challenges ideas about the role of actin in cancer invasion.Cancer progression is modulated by
a balance of oncogenes and tumor
suppressors. Oncogenes promote tumor
formation and growth by a whole host
of mechanisms, including allowing in-
creased proliferation, reducing cell death,
and allowing adhesion-independent cell
survival. Tumor suppressors, on the other
hand, prevent tumor growth and progres-
sion by opposing these phenomena and
also by promoting the normal differenti-
ated state of a tissue. Cancer progresses
partly by deleting or suppressing the
expression or activity of tumor suppres-
sors. Tumors generally have unique and
evolving gene expression signatures,
and it is likely that the human genome
contains several undiscovered tumor
suppressors. Identification of new tumor
suppressors and oncogenes is a major
goal of cancer research, as they may
represent new drug targets.
It was with this aim in mind that Silva
and colleagues used RNAi to target genes
found in regions of chromosomes that are
frequently deleted in tumors (Silva et al.,
2009). They analyzed regions of deletion
that contained no known tumor suppres-
sors in hopes of finding new ones. Of 29
genes tested, CYFIP1 was required for
normal epithelial morphology in organized
mammary cell clusters (acini) formed in
3D matrix.
CYFIP stands for cytoplasmic FMR1
interacting protein, as the CYFIPs were
discovered as proteins that interact with
the fragile-X syndrome mental retardation
(FMR) proteins. There are two known
CYFIP proteins in humans, CYFIP1 (also
p140Sra) and CYFIP2 (also PIR121). The
CYFIP gene is also found at a breakpoint
hotspot for the Prader-Willi/Angelman
syndromes and may be implicated in
autism (Sahoo et al., 2006). The role ofCYFIP1 in these disorders is not well
understood, but CYFIP1 binds directly to
the translation initiation factor eIF4E and
represses translation of FMRP targets in
thebrain (Napoli et al., 2008). Thus, altered
protein translation likely contributes to
these syndromes. However, CYFIP1 also
regulates actin cytoskeletal architecture,
as it is an integral member of the Scar/
WAVE complex. It is not clear whether
protein translation regulation by CYFIP1
is influenced by or completely indepen-
dent of the actin cytoskeletal architecture.
However, Silva and colleagues concluded
that FMR1-CYFIP1 was not involved
in tumor cell invasion, as knockdown
of FMR1 did not affect morphology of
spheroid cultures.
TheScar/WAVEcomplex is aconserved
complex of 5 subunits that stimulates
actin assembly when cells form lamelli-
podia (Figure 1A). The subunits appear to
depend largely on the integrity of the
wholecomplex for their stability, as knock-
down or knockout of individual subunits
often leads to degradation of the whole
complex (Blagg and Insall, 2004). The
Scar/WAVE complex exists in an inactive
state and is activated by signals to
the small GTPase Rac1 that trigger expo-
sure of the Scar/WAVE C-terminal VCA
domain (Figure 1A), leading to activation
of the Arp2/3 complex and assembly of
branched actin structures (Ismail et al.,
2009). This actin assembly produces thin
sheet-like extensions of the plasma
membrane known as lamellipodia and
may also cooperate with other actin regu-
latory proteins to assemble spiky protru-
sions known as filopodia.
Since cells use actin-mediated protru-
sions to migrate, it seems perplexing
that a protein that promotes lamellipodia
formation could act as a suppressor,Cancerather than a promoter, of invasion.
However, there are several possible
explanations for these observations. Silva
and colleagues demonstrated that actin
assembly mediated by CYFIP1 is impor-
tant for the formation of cell-cell and
cell-matrix adhesions. The formation of
cell-cell adherence junctions involves
the interactions of cadherin proteins that
span the plasma membrane and form
homo-oligomers with cadherins on adja-
cent cells. For this process to occur
normally, cells first contact each other
and explore the contact surface using
lamellipodia and filopodia assembled
via Arp2/3 complex and Scar/WAVE-
mediated actin assembly (Yamada and
Nelson, 2007) (Figure 1B). Likewise,
Arp2/3 complex and actin assembly are
important for the formation of integrin-
mediated contacts with the extracellular
matrix (Serrels et al., 2007). Silva and
colleagues demonstrate that loss of
CYFIP1-mediatedactinassemblydisrupts
the architecture of cells via destabilization
of their interactions with each other
and with the matrix. Thus, they conclude
that lamellipodial and filopodial actin
assembly are important for the establish-
ment of normal epithelial architecture.
While disruption of normal tissue archi-
tecture is likely to promote a more inva-
sive phenotype in transformed cells, it still
might seem surprising that loss of lamelli-
podia and filopodia wouldn’t lead to less
invasive cells because of the expected
reduction inmotility. However, it is unclear
what the real role of short-lived highly
dynamic structures like lamellipodia and
filopodia are in cancer cell invasion.
Structures that are much longer lived,
such as invadopodia, may be more rele-
vant for cancer cell invasion, whereas
filopodia and lamellipodia may be morer Cell 16, July 7, 2009 ª2009 Elsevier Inc. 5
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(A) The inactive Scar/WAVE complex is activated upon Rac1 binding, which exposes the C-terminal
VCA domain of Scar/WAVE leading to the Arp2/3 complex activation and assembly of new actin filaments.
CYFIP proteins are the key component of Rac1 binding and complex stabilization. As a result of actin
polymerization, the membrane is extended to generate lamellipodia and/or filopodia.
(B)When cells form cell-cell junctions, cells contact each other with lamellipodia and filopodia. Scar/WAVE
complex and the Arp2/3 complex polymerize actin to drive this process (red outline). Extending lamellipo-
dia or filopodia expands the contact surface between cells. Meanwhile, cadherin proteins accumulate at
the cell-cell contacts. Finally, cadherins seal up the contact to generate cell-cell adherence junctions by
forming homo-oligomers and anchoring actin to the junctions.
(C) Possible mechanisms for enhanced motility of CYFIP1 knockdown epithelial cells. (1) CYFIP1 knock-
down cells may invade without lamellipodia or filopodia using fibroblast-assisted motility. (2) In addition,
the knockdown cells could also invade using membrane bleb- or pseudopod-mediated mechanisms.
These nonactin assembly based mechanisms allow migration of individual cells. (3) The cells could also
invade collectively with a few cells moving with pseudopodia at the front.important during normal morphogenesis
and the formation of cell-cell contacts.
Loss of CYFIP1 could lead to a more
loosely packed tumor.
Cells without CYFIP1 might still be able
to migrate and invade using collective
migration and an alternative mode of
motility that doesn’t need lamellipodia or
filopodia (Figure 1C). This reflects both
the ability of other cells in the microenvi-
ronment, such as fibroblasts, to assist
the motility of the cancer cells (Pinner6 Cancer Cell 16, July 7, 2009 ª2009 Elseviand Sahai, 2008) and the ability of the
cancer cells to use alternate types of
protrusions, such as membrane blebs or
pseudopod extensions to migrate (Sanz-
Moreno et al., 2008). Could loss of Cyfip1
be tipping the balance between lame-
llipodial and bleb-mediated motility in
theseepithelial cells?Silva andcolleagues
coinjected fibroblasts together with kera-
tinocytes to show that loss of Cyfip1
promoted invasion. Thus, the fibroblasts
might assist in collective invasion byer Inc.carving a path in the extracellular matrix
and forminga leading front for the invading
cells (Figure 1C). It has recently been
demonstrated that normal breast devel-
opmentproceedsbyamechanism resem-
bling collective migration and doesn’t
require lamellipodia and filopodia, so it
wouldmake sense if epithelial cancer cells
could use a similar mechanism for inva-
sion (Ewald et al., 2008).
In their discussion, Silva and colleagues
conclude that the invasion suppression
effect of Cyfip1 may be generally due to
a loss in the regulation of actin dynamics.
This interesting hypothesis raises many
questions. It might be of interest to take
a closer look at how actin dynamics are
perturbed by loss of Cyfip1. Presumably,
cells still have Cyfip2 and may, thus, still
have functional Scar/WAVE complex.
Does the Scar/WAVE complex have a
positive role as a component of cell-cell
junctions, or is it perhaps sequestered
there once cell contacts are formed
to prevent further lamellipodia actin
assembly? What turns off Scar/WAVE
once cells form stable contacts? Other
members of the Scar/WAVE complex,
Abi and Nap1, have a role in cell-cell
junctions independently of Scar/WAVE
proteins (Ryu et al., 2009), but it is unclear
if Cyfip1/2 are found at cell-cell junctions.
As imaging techniques and models for
human cancers becomemore accessible,
it is increasingly possible to ask funda-
mental questions about actin dynamics
and its role in vivo, which opens up an
amazing new dimension for future cancer
research.
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In a recent issue of Science, Olive
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Pancreatic cancer remains a major chal-
lenge for all of us. It is the fourth leading
cause of death from cancer in the US,
with an estimated 37,680 people diag-
nosedwith the disease and 34,280 people
dying from the disease each year (Jemal
et al., 2008). Worldwide, more than
213,000 are diagnosed with pancreatic
cancer each year (Koorstra et al., 2008).
It has the worst 1 and 5 year survival of
any cancer. In addition to a poor survival
rate, patients with pancreatic cancer
have a great deal of suffering, with a parti-
cularly high incidence of pain—mostly
caused by a predilection for the tumor to
invade the perineural space of nerves in
the celiac plexus (Zhu et al., 1999). In addi-
tion, substantial weight loss and multiple
gastrointestinal symptoms sap the energy
of patients with the disease. If the above
description of the disease is not bad
enough, there has recently been worse
news (Jones et al., 2008). In a comprehen-
sive genetic analysis of 24 patients’
pancreatic cancers, the authors noted an
average of 63 genetic alterations in each
tumor, the majority of which were point
mutations. However, these alterations
did define a set of 12 recurrent pathways
as possible ways to attack the disease;
the findings remind us just how chal-
lenging pancreatic cancer is to treat.Serrels, B., Serrels, A., Brunton, V.G., Holt, M.,
McLean, G.W., Gray, C.H., Jones, G.E., and
Frame, M.C. (2007). Nat. Cell Biol. 9, 1046–1056.
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It is a mystery as to why so many
currently available anticancer agents
with demonstrated antitumor activity in
in vitro and in vivo tumor models do not
work in patients with pancreatic cancer.
Is it just because of the inherent resistance
or heterogeneity of pancreatic cancer?
Other tumors, such as colon and lung,
have inherent resistance and heteroge-
neity, yet anticancer agents frequently
cause tumor shrinkage and improve
survival for patients with those diseases.
Why is this?
It has been recognized for some period
of time that pancreatic cancers often
demonstrate hypoperfusion (Park et al.,
2009) (Figure 1). Microscopically, almost
a sine qua non of pancreatic cancer
is the dense fibroinflammatory reaction
that invariably accompanies the disease
(Mahadevan and Von Hoff, 2007). This
appearance is also noted with other types
of cancer, such as breast cancer. Could it
be so simple that hypoperfusion explains
why any therapeutic agent simply cannot
get to the tumor cells because the circula-
tion to pancreatic cancer is so poor?
Pancreatic cancer is one of the tumor
types to be consistently hypoxic, possibly
because of hypoperfusion, and it is notori-
ously resistant to antiangiogenic agents
(VanCutsemet al., 2009). If hypoperfusion
CancCordon-Cardo, C., Muthuswamy, S.K., et al.
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is the reason (or at least one of the
reasons) for the resistance of pancreatic
cancers to our therapies, Olive and col-
leagues (2009) have now given us a new
window on how the stroma (the fibroin-
flammatory component of the tumor) may
be altered, possibly improving our ability
todeliveranticancer therapies to the tumor
cells.
Ina seriesofwell-strategizedandcareful
pieces of work, Tuveson and colleagues
have generated genetically engineered
mouse models that closely mimic the
human disease condition (Hingorani et al.,
2003, 2005; Hruban et al., 2006). Of parti-
cular interest is that KPCmice, which con-
ditionally express endogenous mutant
Kras and p53 alleles in pancreatic cells,
have, as a very early histologic feature of
tumorigenesis, the appearance of a char-
acteristic stroma with infiltration of regula-
tory T cells, fibroblasts, and a fibroinflam-
matory component.
In an important follow-up study, Olive
and colleagues (2009) now demonstrate
that an Hh-signaling pathway antagonist
could be used to deplete tumor-associ-
ated stromal tissues and improve the
delivery of one of the few modestly active
anti-pancreatic-cancer agents, gemcita-
bine, into the pancreatic cancer. They
first show that tumors in KPC mice had
er Cell 16, July 7, 2009 ª2009 Elsevier Inc. 7
